Go back

Go to

Partnering with existing owners and management, ARCHIMED acquires majority interest in NAMSA, the world leader in medical device testing




Investment to accelerate NAMSA’s global growth and strategic vision; NAMSA is the third acquisition of MED Platform I, ARCHIMED’s recently closed €1 billion mid-cap buy-and-build fund for the healthcare sector.

September 1, 2020 – Private equity healthcare specialist ARCHIMED has acquired from the founding Gorski Family a majority stake in NAMSA, the only full continuum Contract Research Organization in the world focused exclusively on medical devices. NAMSA’s President and CEO, John Gorski, the Gorski Family and senior managers will hold stakes in the company (amounting to a significant double-digit percentage). The price of the transaction is undisclosed.

NAMSA was the first independent company in the world to focus solely on testing medical device materials for safety. NAMSA’s suite of services are designed to lower development costs and accelerate regulatory approval and commercialization globally for medical device and in vitro diagnotics (IVD) technologies. NAMSA offers expert medical device testing, regulatory, reimbursement and quality consulting services, and clinical research support to aid clients at every stage in the medical device development continuum.

NAMSA is the third acquisition of ARCHIMED’s recently closed €1 billion ($1.2 billion) MED Platform I buy-and-build fund. MED Platform I partners with growth companies in the European and North American mid-cap healthcare sectors, buying majority stakes for €50 million to €500 million in association with existing owners and managers. MED Platform I provides its companies with the strategic, tactical and financial resources they need to broaden product lines, expand into new regions and consolidate sectors.

“Investment from a strategic partner is essential for NAMSA’s next era of growth,” says NAMSA President and CEO John Gorski. “ARCHIMED didn’t just bring financing to the table, they also have a sophisticated understanding of how to achieve success in this industry, particularly through a buy-and-build strategy. ARCHIMED’s impressive global network of relationships in the medical device business will broaden our client base, while the capital access, industry experience and deal acumen we gain will accelerate our international growth, both organically and via acquisition.”

“There is a fantastic cultural fit between ARCHIMED and NAMSA and we share the same vision for the future,” says ARCHIMED Chairman Denis Ribon. “NAMSA is the global leader in a fragmented, fast growing field, bursting with technological innovation. The latter is particularly evident in the area of wearable devices that are increasingly being adapted to diagnose, monitor and manage life threatening medical conditions.” “ARCHIMED and NAMSA see huge potential for growth in the medical device services market across the entire spectrum of testing, clinical trials and consulting,”adds André-Michel Ballester, Managing Partner of the MED Platform I fund.